NeuroOne Medical Technologies (NMTC)
Develops thin-film electrode and ablation systems for neurological diagnosis and treatment.
Something off on this page? Send us feedback.
Develops and commercializes thin-film electrode and ablation systems for neurological diagnosis and treatment. Its single Neuromodulation Products segment sells Evo electrodes and OneRF ablation systems, with revenue also linked to a Zimmer collaboration and distribution arrangement.
Develops and commercializes thin-film electrode and ablation systems for neurological diagnosis and treatment through a single Neuromodulation Products segment. Its commercial offerings include Evo Cortical and Evo sEEG electrodes, plus the OneRF Ablation System and OneRF TN Ablation System.
The platform centers on minimally invasive, high-definition electrodes for diagnostic and therapeutic neurological applications. Evo sEEG uses the same electrode for diagnostic and therapeutic applications, while the OneRF systems extend the portfolio into ablation.
Operations are shaped by FDA clearance requirements, third-party contract manufacturers and suppliers, license agreements, and the Zimmer collaboration and distribution arrangement.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 14, 2026 | Maxim Group | Reiterate | Rating: —Target: $3 | Target: $5 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.0M · Total debt $73.3K · Total assets $6.2M · Shareholders' equity $3.8M
- Revenue
- $2.0M
- Operating income
- −$2.4M
- Net income
- −$2.0M
No dividends on record.
| Institutions | 22.45% | 2.04M shares | |
|---|---|---|---|
| 27 holders · as of Jun 30, 2026 | |||
| Insiders | 19.66% | 1.79M shares | |
| 11 holders · as of Sep 8, 2026 | |||
| Strategic holders | 0.35% | 31.8K shares | |
| 1 holder · as of Apr 4, 2019 | |||
| Other | 57.54% | 5.24M shares | |
| remainder | |||
9.11M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Brian PrattInsider10 percent owner | 11.93% | 1.09M | filed Jul 14, 2026 |
Bleichroeder LPInstitution | 7.32% | 666,666 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.87% | 352,774 | as of Jun 30, 2026 |
Bard Associates IncInstitution | 3.35% | 305,428 | as of Jun 30, 2026 |
Perkins Capital Management IncInstitution | 2.69% | 244,656 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 27, 2026 | David J. Wambeke | officer: Chief Business Officer | +33,333 | $2.01 |
| Jun 30, 2026 | Mark Christianson | officer: Market Development Director | −10,000 | $3.18 |
| Mar 30, 2026 | Mark Christianson | officer: Business Development Director | −15,363 | $0.7400 |
| Mar 13, 2026 | Mark Christianson | officer: Business Development Director | −100 | $0.8000 |
| Mar 12, 2026 | Mark Christianson | officer: Business Development Director | −817 | $0.8000 |
- Medtronic
Named rival in brain soft-tissue ablation.
- ClearPoint Neuro
Named rival in MRI-guided laser brain ablation.
- NeuroPace
Public epilepsy neuromodulation and focal-localization peer.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NeuroOne Medical Technologies | $1.39 | +1.17% | $11.3M | — | — | 1.1 | +16.3% |
| Medtronic | $90.84 | +0.08% | $117.44B | 22.6 | 15.1 | 3.1 | +13.7% |
| ClearPoint Neuro | $15.99 | +1.27% | $419.0M | — | — | 9.9 | +18.1% |
| NeuroPace | $14.71 | −0.07% | $495.7M | — | — | 5.0 | −3.0% |
| Median | 22.6 | 15.1 | 5.0 | +13.7% |